Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Acute Myeloid Leukemia

The diagnosis and management of hematologic malignancies during pregnancy

In this episode of the VJHemOnc podcast, Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, shares…

Date: 16th July 2026

Precision medicine in AML: from targeted therapy to transplantation

This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted…

Date: 22nd June 2026

MRD in ALL and AML: from prognostic marker to clinical endpoint

This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic…

Date: 20th March 2026

Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies

This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025. Amir Fathi, MD, MPH, Massachusetts General Hospital,…

Date: 30th January 2026

Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges

This episode of the VJHemOnc podcast focuses on accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP), offering insights into their diagnosis and…

Date: 20th November 2025

The value and utility of MRD in the management of adults with newly-diagnosed AML

This podcast features experts Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sanam Loghavi, MD, The University…

Date: 14th November 2025

Reviewing recent guideline updates on the risk stratification and treatment of AML

In this episode of the VJHemOnc Podcast, we are joined by Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, and…

Date: 10th October 2025

FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD

This podcast focuses on FLT3-ITD-positive acute myeloid leukemia (FLT3-ITD+ AML), featuring experts Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston,…

Date: 15th August 2025

Treating elderly or unfit patients with AML: current approach and future directions

This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML)….

Date: 4th July 2025

CHIP & CCUS: advances in understanding and should we treat these precursor conditions?

In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown…

Date: 20th June 2025

Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology…

Date: 31st January 2025

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,…

Date: 6th November 2024